

Potential for Scenar Technology in New Zealand

The Scenar

The scenar is a health device that was developed by the Russians for the space programme as a light weight solution that can be used by cosmonauts for a wide variety of ailments. The Russians invested 1000 man-years of scientist time into the development under top military secrecy. It won the Lenin Award in 1988 (the Russian equivalent of the Nobel Prize) and has achieved mainstream use in Russia with 10,000 practitioners. It is in daily use in their hospitals and ambulances.



In 1999 the scenar was introduced into the United Kingdom and from there to other parts of the western world. The sports industry has picked up on the scenar following the success of the Russian use of scenar at the Sydney Olympics. For example the British national soccer team now has four scenars for use with their players and claim healing time is reduced fourfold. Appendix two shows Russian results for 17,309 patients showing total cure for 85% of patients and significant improvement for 95% of patients.

The scenar is a non invasive, non drug dependant, biofeedback device that speeds up the body's own healing process. The scenar is based on research that showed that the body heals itself by creating a positive electrical charge in the area around the injury. This electropositive charge attracts the healing action of the immune system and other restorative elements in our body which operate with an electrically negative charge. With chronic diseases the body habituates to an injury and stops regarding it as something to be repaired. The scenar works to restore the correct electrical polarity in the body so that the healing process can proceed. The scenar also has settings to reduce pain and sympathetic nervous system overloads as well as frequencies that give the body energy to heal. The scenar works to increase the effectiveness of any other treatment that is used by opening up energy pathways in the body.

The main benefits of scenar are to:

- Speed healing across a very wide range of ailments
- Decrease pain
- Reinvigorate the healing process in chronic ailments
- Safe treatment without the side effects common to other forms of treatment
- Long lasting and ongoing improvement after treatment has finished
- Can achieve good results with limited training,
- The Autoscenar, a brand of scenar simplified and developed for home use, can be effectively used with a day's training and requires limited literacy. It is the brand most commonly used by scenar practitioners in New Zealand.
- Radically reduce the cost of providing treatment. Scenar cost between \$850 and \$5000 to purchase.
- Minimal and mild side effects with few contra-indications.

- Most scenar brands run on a standard 9 volt battery which needs to be changed about once every three months if it is being used continuously. This enables the scenar to be used in any setting where there is no power.
- Lightweight. The Autoscenar looks like a small television remote and weighs 200 grams.

Scenar Use in New Zealand

We see potential for the scenar in New Zealand to reduce the cost of medical care, advance healing, and provide first aid care in the hands of laypeople. The health care areas most likely to initially exploit the scenar are:

- Sports injuries with the scenar used by physiotherapists as well as being on hand at sports events – several sporting codes at the regional and national level have developed an interest in trialling the scenar
- Occupational overuse syndrome (termed OOS or RSI) which is chronic and expensive for ACC (\$30 million annually and rising). The scenar awakens the body to heal OOS when it has become so accustomed to the pain that the body has ceased to treat it as an ailment
- Arthritis is another chronic condition causing pain and disability and estimated to cost New Zealand 1.6% of GDP in direct and indirect costs. Like OOS, the condition develops gradually and the body typically acclimatises to the ailment rather than healing it. New Zealand scenar practitioners report remarkable success with reversing arthritis.
- Pain management – recent research from the Royal Melbourne Institute of Technology showed the scenar exceeded morphine for pain management in terminal cancer patients

Early adoption of the scenar is also likely to be on farms, fishing boats, and communities remote from medical care. NZAid may be interested in training villagers to improve health in the Pacific. We have had good success with providing donated scenar to Ugandan villages. The Russians originally developed the scenar for long space voyages as the ultimate remote location without access to a pharmacy, doctor or hospital.

Over the last five years scenar technology has been introduced into New Zealand with a growing number of trained practitioners. These are mainly people in the alternative health sector who have travelled to Britain, America, Bulgaria and Australia for training. These people have set up some local training options.

We see the greatest challenge to the adoption and diffusion of scenar technology in New Zealand is the perception that it is alternative. There is fascinating research on the rapid uptake of high status technologies and the slow uptake of low status technologies in mainstream medicine. Low status technologies are characterised by being low cost; used by alternative practitioners, laypeople or nurses; can be readily taught; are easily accessible; and originate outside wealthy western countries. This makes the scenar an ideal challenge for adoption and diffusion in New Zealand!

APPENDIX 1

Registration

Europe

The scenar 97.4+ has been awarded the CE mark and complies with the European Medical Directive (93/42/EEC). This documentation states it is:

A device for monitoring, treating and alleviating non-specific disease, injury or handicap by supplying low-level electrical energy to the body system in a form that may reduce pain, oedema and inflammation in a manner that allows the natural resources of that body to restore homeostasis more rapidly than if it were left alone.....(by) electrical action on the skin surface activating tissues in the "somatic and autonomous" nervous system...(leading to) the possibility of a therapeutic effect in addition to mediating pain by the production of endorphins. In simple terms scenar Treatment is currently permitted to claim positive efficacy for pain relief and pain management for to use in all countries in the European Union, and is a 'safe device'.

USA

Scenar 97.4+ Biofeedback-controlled. Regulated by the US FDA under 21 CFR 882.5050, Generic Name: Device, Biofeedback, Product Code HCC, Class II exempt from 510(K) pre-market notification according to FDA Notice FR21ja98-84 as a battery-powered, professional use device for relaxation training and muscle education. A Class III FDA approval is pending. Prior to that approval, the manufacturer can only promote use for above in the US.

NEW ZEALAND

Registered with MEDSAFE in Device Category 1. (This is the same registration as the TENS machine).

APPENDIX 2: Summary of Russian Scenar Results published by Yori Gorfinkle, M.D., Taganrog, Russia

Percent cured	84.91%
Percent Improved	94.75%
Average Treatments	12
Average total time (hours)	4.06
Total number of cases	17,309

Details:

Diseases of the Circulation System

	# Patients	Complete Cure	Significant Improvement	Moderate Improvement	Slight Improvement	No Result	% Cured	% Improved
Transient dytonia of blood vessels	682	614	38	10	12	8	90.03	98.83
Essential hypertension	318	261	13	22	8	14	82.08	95.60
Angina pectoris	228	138	42	8	13	14	60.53	88.16
Acute myocadial infarction	31	22	4	3	1	1	70.97	96.77
Sudden cardiac arrest	16	12	0	0	0	4	75.00	75.00
Acute heart failure	48	47	0	0	0	1	97.92	97.92
Ischemic heart disease	92	2	69	4	14	4	2.17	95.65
Cardialgia NOS	104	99	1	1	1	2	95.19	98.08
Hemorrhoids	408	391	14	1	1	1	95.83	99.75
Totals	1245	1586	180	49	50	62	72.46	93.37

Diseases of Digestive System

	# Patients	Complete Cure	Significant Improvement	Moderate Improvement	Slight Improvement	No Result	% Cured	% Improved
Gastritis and duodenitis	1,018	1002	12	1	1	2	98.43	99.80
Gastric and Duodenal Ulcers	341	228	13	26	2	12	66.86	78.89
Enteritis (mainly non-infectious)	182	182	0	0	0	0	100	100
Colitis	302	263	20	10	3	6	87.09	98.01
Cholecystitis	218	145	6	10	3	4	66.51	75.23
Hepatitis/Hepatic Failure	48	47	0	0	0	1	97.92	97.92
Pancreatitis (Acute and Chronic)	63	63	0	0	0	0	100	100
Totals	2,172	1,930	51	47	9	25	88.12	92.84

Diseases & Trauma of Musculoskeletal System

	# Patients	Complete Cure	Significant Improvement	Moderate Improvement	Slight Improvement	No Result	% Cured	% Improved
Arthropathies (arthritis, arthrosis, etc.)	1,238	753	280	114	61	30	60.82	97.58
Dorsopathies (deformations, spondylosis)	2,352	2,048	252	35	17	2	87.07	100
Radiculopathy (trapped nerve)	1,820	1,670	102	40	6	2	91.76	99.89
Neuralgia (cervicalgia, lumbago, sciatica)	605	582	17	6	0	0	96.20	100
Myositis	840	839	0	0	0	1	99.88	99.88
Ligament strain	108	108	0	0	0	0	100	100
Superficial injury of soft tissues	325	325	0	0	0	0	100	100
Unknown pain (soft tissues and bones)	32	28	1	1	1	1	87.50	96.88
Totals	7,320	6,353	652	196	85	36	90.40	99.28

Diseases of Respiratory System

	# Patients	Complete Cure	Significant Improvement	Moderate Improvement	Slight Improvement	No Result	% Cured	% Improved
Acute nasopharyngitis (common cold)	608	601	6	0	0	1	98.85	99.84
Acute upper respiratory viral infection	345	345	0	0	0	0	100	100
Influenza	104	104	0	0	0	0	100	100
Acute Tonsillitis and pharyngitis	328	314	14	0	0	0	95.73	100
Acute Sinusitis	221	218	3	0	0	0	98.64	100
Acute Laryngitis and tracheitis	402	380	18	2	0	0	94.53	99.50
Acute Bronchitis	615	562	24	15	7	7	91.38	98.86
Pneumonia	138	116	14	2	3	3	84.06	97.83
Asthma	82	31	15	22	7	7	37.80	91.46
Acute respiratory failure	15	14	0	0	0	1	93.33	93.33
Acute edema of the lung	12	11	0	0	0	1	91.67	91.67
Pleurisy	38	22	2	1	1	1	86.84	97.37
Totals	2,908	2,729	96	42	18	21	89.40	97.49

Urogenital Diseases (Female)

	# Patients	Complete Cure	Significant Improvement	Moderate Improvement	Slight Improvement	No Result	% Cured	% Improved
Mastopathy	264	220	8	16	3	18	83.33	93.56
Acute Mastitis	88	88	0	0	0	0	100	100
Salpingitis/ovarian cyst	608	604	1	1	1	1	99.34	99.84
Endometriosis	126	98	4	10	7	7	77.78	94.44
Fibromyoma of uterus	201	116	38	21	3	23	57.71	88.56
Erosion of cervix uteri	120	119	0	0	0	1	99.71	99.71
Dysmnenorrhea (menstrual cycle disorders)	180	112	30	12	0	26	62.22	85.56
Female infertility	86	63	0	0	0	23	73.26	73.26
Frigidity	38	18	6	7	1	6	47.37	84.21
Totals	1,447	1,438	87	67	15	105	77.11	90.63

Urogenital Diseases (Male)

	# Patients	Complete Cure	Significant Improvement	Moderate Improvement	Slight Improvement	No Result	% Cured	% Improved
Pyelonephritis (Acute and Chronic)	402	384	4	7	3	4	95.52	99.00
Urinary calculi	161	140	7	6	5	3	86.96	98.14
Cystitis	208	207	0	0	0	1	99.52	99.52
Urethritis	24	22	1	0	0	1	91.67	95.83
Prostatitis (Acute and Chronic)	605	602	3	0	0	1	99.50	100
Hyperplasia of prostate	88	63	7	3	8	7	71.59	92.05
Male infertility	62	44	0	0	0	18	70.97	70.97
Impotence	322	269	14	0	0	48	80.75	85.09
Totals	1,872	1,722	36	16	16	83	87.06	92.58

Diseases of the Ear

	# Patients	Complete Cure	Significant Improvement	Moderate Improvement	Slight Improvement	No Result	% Cured	% Improved
Otitis	144	144	0	0	0	0	100	100
Hearing Loss	85	68	11	4	0	2	80.00	97.65
Abnormal auditory perception	116	98	4	2	4	8	84.48	93.10